Elevation Oncology Inc [NASDAQ: ELEV] slipped around -0.2 points on Thursday, while shares priced at $0.28 at the close of the session, down -41.82%.
Compared to the average trading volume of 2.22M shares, ELEV reached a trading volume of 17590469 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Elevation Oncology Inc [ELEV]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ELEV shares is $2.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ELEV stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for Elevation Oncology Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 03, 2025. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on May 31, 2024, representing the official price target for Elevation Oncology Inc stock. Previously, the target price had yet another raise to $8, while Stephens analysts kept a Overweight rating on ELEV stock.
The Average True Range (ATR) for Elevation Oncology Inc is set at 0.06 The Price to Book ratio for the last quarter was 0.27, with the Price to Cash per share for the same quarter was set at 1.57.
How has ELEV stock performed recently?
Elevation Oncology Inc [ELEV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -44.23. With this latest performance, ELEV shares dropped by -57.24% in over the last four-week period, additionally sinking by -53.94% over the last 6 months – not to mention a drop of -93.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ELEV stock in for the last two-week period is set at 22.51, with the RSI for the last a single of trading hit 16.57, and the three-weeks RSI is set at 27.73 for Elevation Oncology Inc [ELEV]. The present Moving Average for the last 50 days of trading for this stock 0.6049, while it was recorded at 0.4592 for the last single week of trading, and 1.1190 for the last 200 days.
Elevation Oncology Inc [ELEV]: Deeper insight into the fundamentals
Elevation Oncology Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 21.21 and a Current Ratio set at 21.21.
Earnings analysis for Elevation Oncology Inc [ELEV]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ELEV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Elevation Oncology Inc go to 1.36%.
Insider trade positions for Elevation Oncology Inc [ELEV]
There are presently around $67.77%, or 67.98%% of ELEV stock, in the hands of institutional investors. The top three institutional holders of ELEV stocks are: LOGOS GLOBAL MANAGEMENT LP with ownership of 3.85 million shares, which is approximately 6.5234%. FARALLON CAPITAL MANAGEMENT LLC, holding 3.6 million shares of the stock with an approximate value of $$9.72 million in ELEV stocks shares; and FARALLON CAPITAL MANAGEMENT LLC, currently with $$8.26 million in ELEV stock with ownership which is approximately 5.1848%.
